Convection-enhanced delivery (CED) uses precisely controlled pressure to infuse therapeutic agents directly into brain tissue or tumors via microcatheters. For oncology indications, CED aims to achieve therapeutic drug concentrations across a larger volume of tumor and surrounding brain while minimizing systemic exposure.

Prior CED approaches—especially for diffuse intrinsic pontine glioma (DIPG) and other diffuse tumors—often required repeated surgeries to place and remove single-use catheters. Those procedures increased risk, limited treatment continuity, and constrained drug distribution.

The Neurochase Chronic Drug Delivery System (under development) is designed to these challenges. It combines semi‑permanent intracranial catheters with a low‑profile, skull‑mounted port to enable repeated, intermittent CED sessions over months or years in awake patients, improving safety, treatment coverage, and logistical flexibility.

Use of the Neurochase system is currently limited to approved pre-clinical studies and clinical trials. We are actively seeking biopharma partners interested in employing the Chronic Drug Delivery System for delivery of gene therapies or Antisense Oligonucleotides (ASOs) across oncology and non-oncology indications including neurodegenerative diseases.